ArticleFrontiers in veterinary science2025
Case Report: Transient myocardial thickening in a cat secondary to acute cholangiohepatitis.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Arterial Thromboembolism in a Seven-Month-Old Cat with Acute Myocardial Injury.Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient myocardial thickening (TMT) has been reported mainly in young cats following systemic triggers such as anesthesia, surgery, acute stress, or infection; however, to the authors' knowledge, TMT secondary to acute cholangiohepatitis has not been described. A 3-year-old, 5.8-kg castrated male Abyssinian was referred with acute cholangiohepatitis. Initial evaluation revealed increased hepatic enzymes and bilirubin, elevated cardiac troponin I (cTnI, 3.5 ng/mL), and mildly increased N-terminal pro-B-type natriuretic peptide (NT-proBNP, 102.6 pmol/L). On the day of discharge, despite improving hepatic indices, cTnI rose abruptly to 8.0 ng/mL and NT-proBNP exceeded 1,500 pmol/L. Echocardiography demonstrated septal thickening, left atrial enlargement, and systolic anterior motion of the mitral valve, consistent with TMT. Atenolol was added to the outpatient medical management for cholangiohepatitis, consisting of broad-spectrum antimicrobials, hepatoprotectants, and antiemetic/gastroprotective agents. Over the course of 84 days, five follow-up evaluations were performed, during which hepatic values normalized, cTnI and NT-proBNP returned to reference ranges, and myocardial dimensions and vertebral heart score normalized. Unlike most reports in which TMT is identified after congestive signs develop, this case was recognized earlier, on the basis of an abrupt biomarker surge during apparent clinical improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.